Cetuximab hypersensitivity infusion reactions: Incidence and risk factors

Journal of Oncology Pharmacy Practice

Volumn 19, Issue 3, 2013, Pages 222-227

  Hopps, Sarah ^a   Medina, Patrick ^a   Pant, Shubham ^b   Webb, Ryan ^a   Moorman, Meredith ^a   Borders, Emily ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Anaphylaxis; drug hypersensitivity prevention and control; immunology; incidence; monoclonal antibodies; risk factors

Indexed keywords

ANTIHISTAMINIC AGENT; BRONCHODILATING AGENT; CETUXIMAB; DIPHENHYDRAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; STEROID;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CHEMORADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPERSENSITIVITY INFUSION REACTION; INCIDENCE; INFUSION RELATED REACTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SMOKING; STEROID THERAPY; TREND STUDY; UNIVERSITY HOSPITAL; UTERINE CERVIX CANCER;

ANAPHYLAXIS; DRUG HYPERSENSITIVITY/PREVENTION AND CONTROL; IMMUNOLOGY; INCIDENCE; MONOCLONAL ANTIBODIES; RISK FACTORS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84882278678     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155212462440     Document Type: Article

References (14)

1. Bristol-Myers Squibb. Cetuximab (Erbitux) package insert. New York, January 2012.
2. Zhang H, Berezov A, Wang Q, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007 ; 117 (8). 2051-2058
3. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006 ; 33 (4). 369-385
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximabmonotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004 ; 351 (4). 337-345
5. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008 ; 358 (11). 1109-1117
6. George TJ, Laplant KD, Walden EO, et al. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment. J Support Oncol. 2010 ; 8 (2). 72-77
7. Hansen NL, Chandiramani DV, Morse MA, et al. Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. J Oncol Pharm Pract. 2011 ; 17 (2). 125-130
8. O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007 ; 25 (24). 3644-3648
9. Schwartzberg LS, Stepanski EJ, Fortner BV, et al. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer. 2008 ; 16 (4). 393-398
10. Tronconi MC, Sclafani F, Rimassa L, et al. Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection. J Clin Oncol. 2011 ; 29: e680-681
11. Foley KA, Wang PF, Barber BL, et al. Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Ann Oncol. 2010 ; 21 (7). 1455-1461
12. 'Common Terminology Criteria for Adverse Events version 4.0', UDHHS, NIH, NCI, http://ctep.cancer.gov/protoclDevelopment/electronic-applications/ctc. htm#ctc-40 (accessed 2 August 2010).
13. Siena S, Glynne-Jones R, Adenis A, et al. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer. 2010 ; 116 (7). 1827-1837
14. Mariotte D, Dupont B, Gervais R, et al. Anti-cetuximabIgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. MAbs. 2011 ; 3 (4). 396-401